Current status of cancer immunotherapy
To prove clinical benefits of cancer vaccine is currently difficult, except for one phase III trial has documented improved overall survival with the vaccine, Sipuleucel‑T, although induction of anti-tumor immune responses through cancer vaccine is theoretically promising and would be straightforwar...
שמור ב:
| מחבר ראשי: | |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
GN Corporation Limited
2014-04-01
|
| סדרה: | Journal of Stem Cells and Regenerative Medicine |
| נושאים: | |
| גישה מקוונת: | http://www.pubstemcell.com/monthly/010010200003.htm |
| תגים: |
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|